Issue 24-5, 2025

Review

https://doi.org/10.38025/2078-1962-2025-24-5-142-157

Adherence to Treatment in Common Chronic Noncommunicable Diseases: Current Challenges for Physicians and the Healthcare System. A Literature Review

View article (Download PDF file)



Download XML file

ORCID Tatiana V. Apkhanova *, ORCID Larisa A. Marchenkova , ORCID Tatiana V. Konchugova

National Association of Experts in Comorbid Neurology, Moscow, Russia


ABSTRACT

INTRODUCTION.  Adherence to treatment, that is, the patient’s strict compliance with the treatment regimen prescribed by the doctor, is an important problem of modern healthcare around the world.

AIM.  Analysis of modern foreign and Russian studies on the importance of adherence to drug therapy in patients with cardiovascular diseases and diabetes mellitus.

MATERIALS AND METHODS.  90 sources from international and domestic databases published for 2025 were analyzed.

RESULTS AND DISCUSSION.  Up-to-date information is provided on the terminology, scale of the problem, and economic losses from low adherence to treatment, typical for patients with chronic non-communicable diseases. Adherence factors associated with the drug itself (price, frequency of administration, number of prescribed drugs), with the patient’s personal qualities and medical characteristics (forgetfulness, age, gender, diagnosis and concomitant pathology, history of complications, education, quality of life), with insufficient awareness of the disease and/or drugs, side effects were determined.

CONCLUSION.  Thus, the patient’s adherence to drug therapy is determined by a large number of heterogeneous factors, the identification of which is an important step towards choosing the optimal method of influencing the patient’s motivation, behavior and choice. It is also often problematic to build a partnership between a doctor and a patient due to the peculiarities of the clinical picture, the psychological characteristics of certain groups of patients or the low quality of the organization of medical care.

KEYWORDS: adherence to treatment, compliance, fixed combination, motivational counseling, cognitive behavioral therapy, arterial hypertension, chronic heart failure, diabetes mellitus

FOR CITATION:

Apkhanova T.V., Marchenkova L.A., Konchugova T.V. Adherence to Treatment in Common Chronic Noncommunicable Diseases: Current Challenges for Physicians and the Healthcare System. A Literature Review. Bulletin of Rehabilitation Medicine. 2025; 24(5): 142-157. https://doi.org/10.38025/2078-1962-2025-24-5-142-157 (In Russ.). 

(In Russ.).] 

FOR CORRESPONDENCE:

Tatiana V. Apkhanova, Е-mail: apkhanovatv@nmicrk.ru


References:

  1. Di Martino M. Una compressa la mattina e mezza la sera: l’aderenza ai trattamenti farmacologici. Recenti Prog Med. 2017; 108(4):165–167. https://doi.org/10.1701/2681.27450
  2. Brown M.T., Bussell J.K. Medication adherence: WHO cares? Mayo Clin Proc 2011; 86: 304–14. https://doi.org/10.4065/mcp.2010.0575
  3. World Health Organization. Sabaté E. Adherence to long-term therapies: evidence for action. 2003; 110 p. Available at: https://iris.who.int/handle/10665/42682 (Accessed: 01.08.2025).
  4. DiMatteo M.R., Giordani P.J., Lepper H.S., Croghan T.W. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002; 40(9): 794–811. https://doi.org/10.1097/00005650-200209000-00009
  5. Jackson C., Eliasson  L., Barber N., Weinman J. Applying COM-B to medication adherence. Eur Health Psychol. 2014; 16(1): 7–17.
  6. IMS Institute for Healthcare Informatics. Advancing the responsible use ofmedicines: Applying levers for change. October 2012. Available at: https://pharmanalyses.fr/wp-content/uploads/2012/10/Advancing-Responsible-Use-of-Meds-Report-01-10-12.pdf (Accessed: 01.08.2025).
  7. Sackett D.L., Haynes R.B., Gibson E.S., et. al. Patient compliance with antihypertensive regimens. Patient Couns Health Educ. 1978; 1(1): 18–21. https://doi.org/10.1016/s0738-3991(78)80033-0
  8. World Health Organization / Geneva. Adherence to long-term treatments. Evidence for action. WHO; 2004. Available at: https://apps.who.int/iris/bitstream/handle/10665/42682/9241545992.pdf (Accessed: 01.08.2025).
  9. Vrijens B., De Geest S., Hughes D.A., et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012; 73(5): 691–705. https://doi.org/10.1111/j.1365-2125.2012.04167.x
  10. For the National Coordinating Centre for NHS Service Delivery and Organisation R & D (NCCSDO). Concordance, adherence and compliance in medicine taking. Report. December 2005. 2005; 309 p. Available at: https://www.ahpo.net/assets/NCCSDO%20Compliance%202005.pdf (Accessed: 01.08.2025).
  11. Ястребов В.С. Проблемы патернализма и партнерства в психиатрии. Психиатрия. 2012; 4(56): 7–13. [Yastrebov V.S. Problems of Paternalism and Partnership in Psychiatry. Psikhiatriya = Psychiatry (Moscow). 2012; 4(56): 7–13 (In Russ.).]
  12. Данилов Д.С. Терапевтическое сотрудничество (комплаенс): содержание понятия, механизмы формирования и методы оптимизации. Неврология, нейропсихиатрия, психосоматика. 2014; 6(2): 4–12. https://doi.org/10.14412/2074-2711-2014-2-4-12 [Danilov D. Therapeutic collaboration (compliance): Content of the definition, mechanisms of formation, and methods of optimization. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2014; 6(2): 4–12. https://doi.org/10.14412/2074-2711-2014-2-4-12 (In Russ.).]
  13. Urquhart J., Vrijens B. New findings about patient adherence to prescribed drug dosing regimens: an introduction to pharmionics. Eur J Hospital Pharm Sci. 2005; 11(5): 103–106.
  14. Cho J.Y., Wilson F.A., Chaikledkaew U., et al. Projected cost savings with optimal medication adherence in patients with cardiovascular disease requiring lipid-lowering therapy: a multinational economic evaluation study. Journal of the American Heart Association. 2024; 13(22): e037792. https://doi.org/10.1161/JAHA.124.037792
  15. Khan R., Socha-Dietrich K. Investing in medication adherence improves health outcomes and health system efficiency: Adherence to medicines for diabetes, hypertension, and hyperlipidaemia. OECD Health Working Papers. 2018; 105. https://doi.org/10.1787/8178962c-en
  16. Gaziano J.M. Global Burden of Cardiovascular Disease. In: Braunnwald E., Zipes D.P., Libby P., editors. Heart Disease: A Textbook of cardiovascular medicine. 6th ed. Philadelphia: W.B. Saunders Company. 2001; pp. 1–17.
  17. European Association for Cardiovascular Prevention & Rehabilitation; Reiner Z., Catapano A.L., De Backer G., et al.; ESC Committee for Practice Guidelines (CPG) 2008–2010 and 2010–2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011; 32(14): 1769–1818. https://doi.org/10.1093/eurheartj/ehr158
  18. Briffa T.G., Hobbs M.S., Tonkin A., et al. Population trends of recurrent coronary heart disease event rates remain high. Circ Cardiovasc Qual Outcomes. 2011; 4(1): 107–113. https://doi.org/10.1161/circoutcomes.110.957944
  19. Chowdhury R., Khan H., Heydon E., et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013; 34(38): 2940–2948. https://doi.org/10.1093/eurheartj/eht295
  20. Dilla T., Valladares A., Lizán L., Sacristán J.A. Adherencia y persistencia terapéutica: causas, consecuencias y estrategias de mejora [Treatment adherence and persistence: causes, consequences and improvement strategies]. Aten Primaria. 2009; 41(6): 342–348. https://doi.org/10.1016/j.aprim.2008.09.031 (In Spanish).
  21. Solera G., Solera J., Tárraga L., et al. Evaluación de la efectividad del farmacéutico en la mejora de la adherencia terapéutica de pacientes con diabetes mellitus tipo 2: revisión sistemática y meta-análisis. Med Gen Fam. 2018; 7(2): 60–65. http://doi.org/10.24038/mgyf.2018.029
  22. Gagnon M.D., Waltermaurer E., Martin A., et al. Patient Beliefs Have a Greater Impact Than Barriers on Medication Adherence in a Community Health Center. J Am Board Fam Med. 2017; 30(3): 331–336. https://doi.org/10.3122/jabfm.2017.03.160129
  23. Yang C., Hui Z., Zeng D., et al. Examining and adapting the information-motivation-behavioural skills model of medication adherence among community-dwelling older patients with multimorbidity: protocol for a cross-sectional study. BMJOpen. 2020; 10: e033431. https://doi.org/10.1136/bmjopen-2019-033431
  24. Duffy E.Y., Ashen D., Blumenthal R.S., et al. Communication approaches to enhance patient motivation and adherence in cardiovascular disease prevention. Clin Cardiol. 2021; 44(9): 1199–1207. https://doi.org/10.1002/clc.23555
  25. Miller V., Nambiar L., Saxena M., et al. Exploring the Barriers to and Facilitators of Using Evidence-Based Drugs in the Secondary Prevention of Cardiovascular Diseases: Findings From a Multistakeholder, Qualitative Analysis. Glob Heart. 2018; 13(1): 27–34.e17. https://doi.org/10.1016/j.gheart.2017.08.001
  26. Reason J. Human error: models and management. BMJ. 2000; 320(7237): 768–770. https://doi.org/10.1136/bmj.320.7237.768
  27. European Commission/Medi-Voice. MEDI-VOICE Report Summary. Project ID: 17893. European Union/European Commission. 2011. [Ref list]. Available at: https://cordis.europa.eu/project/id/17893/reporting (Accessed: 01.08.2025).
  28. Carbonell-Soliva Á., Nouni-García R., López-Pineda A., et al. Opinions and perceptions of patients with cardiovascular disease on adherence: a qualitative study of focus groups. BMC Prim Care. 2024; 25(1): 59. https://doi.org/10.1186/s12875-024-02286-8
  29. Piepoli M.F., Hoes A.W., Agewall S., et al. ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 37(29): 2315–2381. https://doi.org/10.1093/eurheartj/ehw106
  30. Kvarnström K., Airaksinen M., Liira H. Barriers and facilitators to medication adherence: a qualitative study with general practitioners. BMJ Open. 2018; 8(1): e015332. https://doi.org/10.1136/bmjopen-2016-015332
  31. Desai N.R., Farbaniec M., Karalis D.G. Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease. Clin Cardiol. 2023; 46(1): 13–21. https://doi.org/10.1002/clc.23935
  32. Carratalá-Munuera C., Cortés-Castell E., Márquez-Contreras E., et al. Barriers and solutions to improve therapeutic adherence from the Perspective of Primary Care and hospital-based Physicians. Patient Prefer Adherence. 2022; 16: 697–707. https://doi.org/10.2147/PPA.S319084
  33. Simon S.T., Kini V., Levy A.E., Ho P.M. Medication adherence in cardiovascular medicine. BMJ. 2021; 374: n1493. https://doi.org/10.1136/bmj.n1493
  34. Čulig J., Leppée M. From Morisky to Hill-Bone; self-reports scales for measuring adherence to medication. Collegium antropologicum. 2014; 38: 55–62.
  35. Morisky D.E., Ang A., Krousel-Wood M., Ward H.J. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008; 10: 348–354. https://doi.org/10.1111/j.1751-7176.2008.07572.x
  36. Cutler R.L., Fernandez-Llimos F., Frommer M., et al. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open. 2018; 8: e016982. https://doi.org/10.1136/bmjopen-2017-016982
  37. Jackevicius C.A., Li P., Tu J.V. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation. 2008; 117: 1028–1036. https://doi.org/10.1161/circulationaha.107.706820
  38. Ho P.M., Spertus J.A., Masoudi F.A., et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006; 166: 1842–1847. https://doi.org/10.1001/archinte.166.17.1842
  39. Kramer J.M., Hammill B., Anstrom K.J., et al. National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. Am Heart J. 2006; 152: 454.e1–454.e8. https://doi.org/10.1016/j.ahj.2006.02.030
  40. Bansilal S., Castellano J.M., Garrido E., et al. Assessing the impact of medication adherence on long-term cardiovascular outcomes. J Am Coll Cardiol. 2016; 68: 789–801. https://doi.org/10.1016/j.jacc.2016.06.005
  41. Boggon R., van Staa T.P., Timmis A., et al. Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction--a hospital registry-primary care linked cohort (MINAP-GPRD). Eur Heart J. 2011; 32: 2376–2386. https://doi.org/10.1093/eurheartj/ehr340
  42. Rosenbaum L. Beyond belief--how people feel about taking medications for heart disease. N Engl J Med. 2015; 372: 183–187. https://doi.org/10.1056/nejmms1409015
  43. Lauffenburger J.C, Isaac T., Bhattacharya R., et al. Prevalence and impact of having multiple barriers to medication adherence in nonadherent patients with poorly controlled cardiometabolic disease. Am J Cardiol. 2020; 125: 376–382. https://doi.org/10.1016/j.amjcard.2019.10.043
  44. Gaalema D.E., Elliott R.J., Morford Z.H., et al. Effect of socioeconomic status on propensity to change risk behaviors following myocardial infarction: implications for healthy lifestyle medicine. Prog Cardiovasc Dis. 2017; 60: 159–168. https://doi.org/10.1016/j.pcad.2017.01.001
  45. Khera R., Valero-Elizondo J., Das S.R., et al. Cost-related medication nonadherence in adults with atherosclerotic cardiovascular disease in the United States, 2013 to 2017. Circulation. 2019; 140: 2067–2075. https://doi.org/10.1161/circulationaha.119.041974
  46. Luiza V.L., Chaves L.A., Silva R.M., et al. Pharmaceutical policies: effects of cap and co-payment on rational use of medicines. Cochrane Database Syst Rev. 2015; 5: CD007017. https://doi.org/10.1002/14651858.cd007017.pub2
  47. Doll J.A., Hellkamp A.S., Goyal A., et al. Treatment, outcomes, and adherence to medication regimens among dual Medicare-Medicaid-eligible adults with myocardial infarction. JAMA Cardiol. 2016; 1: 787–794. https://doi.org/10.1001/jamacardio.2016.2724
  48. Dhaliwal K.K., King-Shier K., Manns B.J., et al. Exploring the impact of financial barriers on secondary prevention of heart disease. BMC Cardiovasc Disord. 2017; 17: 61. doi: 10.1186/s12872-017-0495-4.
  49. Arora S., Shemisa K., Vaduganathan M., et al. Premature ticagrelor discontinuation in secondary prevention of atherosclerotic CVD: JACC review topic of the week. J Am Coll Cardiol. 2019; 73: 2454–2464. https://doi.org/10.1016/j.jacc.2019.03.470
  50. Verma A.A., Khuu W., Tadrous M., et al. Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study. PLoS Med. 2018; 15: e1002584. https://doi.org/10.1371/journal.pmed.1002584
  51. Muñoz D., Uzoije P., Reynolds C,. et al. Polypill for cardiovascular disease prevention in an underserved population. N Engl J Med. 2019; 381: 1114–1123. https://doi.org/10.1056/nejmoa1815359
  52. Schwalm J.D., Ivers N.M., Natarajan M.K., et al. Cluster randomized controlled trial of Delayed Educational Reminders for Long-term Medication Adherence in ST-Elevation Myocardial Infarction (DERLA-STEMI). Am Heart J. 2015; 170: 903–913. https://doi.org/10.1016/j.ahj.2015.08.014
  53. Ivers N.M., Schwalm J.D., Bouck Z., et al. Interventions supporting long term adherence and decreasing cardiovascular events after myocardial infarction (ISLAND): pragmatic randomised controlled trial. BMJ. 2020; 369: m1731. https://doi.org/10.1136/bmj.m1731
  54. Faridi K.F., Peterson E.D., McCoy L.A., et al. Timing of first postdischarge follow-up and medication adherence after acute myocardial infarction. JAMA Cardiol. 2016; 1: 147–155. https://doi.org/10.1001/jamacardio.2016.0001
  55. Du L., Dong P., Jia J., et al. Impacts of intensive follow-up on the long-term prognosis of percutaneous coronary intervention in acute coronary syndrome patients — a single center prospective randomized controlled study in a Chinese population. Eur J Prev Cardiol. 2016; 23: 1077–1085. https://doi.org/10.1177/2047487315607041
  56. Chen C., Li X., Sun L., et al. Post-discharge short message service improves short-term clinical outcome and self-care behaviour in chronic heart failure. ESC Heart Fail. 2019; 6: 164–173. https://doi.org/10.1002/ehf2.12380
  57. Rinfret S., Rodés-Cabau J., Bagur R., et al., EASY-IMPACT Investigators. Telephone contact to improve adherence to dual antiplatelet therapy after drug-eluting stent implantation. Heart. 2013; 99: 562–569. https://doi.org/10.1136/heartjnl-2012-303004
  58. Choudhry N.K., Krumme A.A., Ercole P.M., et al. Effect of reminder devices on medication adherence: the REMIND randomized clinical trial. JAMA Intern Med. 2017; 177: 624–631. https://doi.org/10.1001/jamainternmed.2016.9627
  59. Derose S.F., Green K., Marrett E., et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Intern Med. 2013; 173: 38–43. https://doi.org/10.1001/2013.jamainternmed.717
  60. Adler A.J., Martin N., Mariani J., et al. Mobile phone text messaging to improve medication adherence in secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017; 4: CD011851. https://doi.org/10.1002/14651858.cd011851.pub2
  61. Thakkar J., Kurup R., Laba T.L., et al. Mobile telephone text messaging for medication adherence in chronic disease: a meta-analysis. JAMA Intern Med. 2016; 176: 340–349. https://doi.org/10.1001/jamainternmed.2015.7667
  62. Rollnick S., Butler C.C., Kinnersley P., et al. Motivational interviewing. BMJ. 2010; 340: c1900. https://doi.org/10.1136/bmj.c1900
  63. Palacio A., Garay D., Langer B., et al. Motivational interviewing improves medication adherence: a systematic review and meta-analysis. J Gen Intern Med. 2016; 31: 929–940. https://doi.org/10.1007/s11606-016-3685-3
  64. Xavier D., Gupta R., Kamath D., et al. Community health worker-based intervention for adherence to drugs and lifestyle change after acute coronary syndrome: a multicentre, open, randomised controlled trial. Lancet Diabetes Endocrinol. 2016; 4: 244–253. https://doi.org/10.1016/s2213-8587(15)00480-5
  65. Yancy C.W., Jessup M., Bozkurt B., et al., American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013; 62: e147–e239. https://doi.org/10.1016/j.jacc.2013.05.019
  66. Grundy S.M, Stone N.J., Bailey A.L., et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019; 139: e1082–e1143. https://doi.org/10.1161/CIR.0000000000000625
  67. Кобалава Ж.Д., Конради А.О., Недогода С.В. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25(3): 3786. https://doi.org/10.15829/1560-4071-2020-3-3786 [Kobalava Z.D., Konradi A.O., Nedogoda S.V., et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020; 25(3): 3786. https://doi.org/10.15829/1560-4071-2020-3-3786 (In Russ.).]
  68. Бойцов С.А., Карпов Ю.А., Логунова Н.А., Бурцев Ю.П., Квасников Б.Б., Хомицкая Ю.В. Пути повышения приверженности к антигипертензивной терапии. Российский кардиологический журнал. 2022; 27(9): 5202. https://doi.org/10.15829/1560-4071-2022-5202 [Boytsov S.A., Karpov Yu.A., Logunova N.A., et al. Ways to increase adherence to antihypertensive therapy. Russian Journal of Cardiology. 2022; 27(9): 5202. https://doi.org/10.15829/1560-4071-2022-5202 (In Russ.).]
  69. Баланова Ю.А., Шальнова С.А., Имаева А.Э. и др. Распространенность артериальной гипертонии, охват лечением и его эффективность в Российской Федерации (данные наблюдательного исследования ЭССЕ-РФ-2). Рациональная Фармакотерапия в Кардиологии. 2019; 15(4): 450–466. https://doi.org/10.20996/1819-6446-2019-15-4-450-466 [Balanova Y.A., Shalnova S.A., Imaeva A.E., et al. on behalf of ESSE-RF-2 researchers. Prevalence, Awareness, Treatment and Control of Hypertension In Russian Federation (Data of Observational ESSE-RF-2 Study). Rational Pharmacotherapy in Cardiology. 2019; 15(4): 450–466. https://doi.org/10.20996/1819-6446-2019-15-4-450-466 (In Russ.).]
  70. Фомин И.В., Поляков Д.С., Бадин Ю.В. и др. Артериальная гипертония в Европейской части Российской Федерации с 1998 по 2007 год: чего мы добились на популяционном уровне? Сердце: журнал для практикующих врачей. 2016; 15(5): 369–378. [Fomin I.V., Polyakov D.S., Badin Yu.V., et аl. Arterial hypertension in European Russia from 1998 to 2007: What did we achieve at the population level? Russian Heart Journal. 2016; 15(5): 369–378 (In Russ.).]
  71. Драпкина О.М., Шепель Р.Н., Дроздова Л.Ю. и др. Качество диспансерного наблюдения взрослого населения с артериальной гипертонией 1–3 степени, за исключением резистентной артериальной гипертонии, врачами-терапевтами участковыми медицинских организаций субъектов Российской Федерации. Российский кардиологический журнал. 2021; 26(4): 4332. https://doi.org/10.15829/1560-4071-2021-4332 [Drapkina O.M., Shepel R.N., Drozdova L.Yu., et al. Quality of follow-up monitoring of the adult population with grade 1-3 hypertension, with the exception of resistant hypertension, by primary care physicians in different Russian regions. Russian Journal of Cardiology. 2021; 26(4): 4332. https://doi.org/10.15829/1560-4071-2021-4332 (In Russ.).]
  72. Corrao G., Parodi A., Nicotra F., et al. Better compliance to antihypertensive medica- tions reduces cardiovascular risk. J Hypertens. 2011; 29: 610–618. https://doi.org/10.1097/hjh.0b013e328342ca97
  73. Parati G., Kjeldsen S., Coca A., et al. Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension. Hypertension. 2021; 77: 692–705. https://doi.org/10.1161/hypertensionaha.120.15781
  74. Карпов Ю.А., Горбунов В.М., Логунова Н.А. Применение тройной фиксированной комбинации в лечении артериальной гипертензии — возможность эффективного контроля артериального давления при использовании комбинированной антигипертензивной терапии: основные результаты Российского наблюдательного исследования ТРИКОЛОР. Российский кардиологический журнал. 2020; 25(10): 4130. https://doi.org/10.15829/1560-4071-2020-4130 [Karpov Yu.A., Gorbunov V.M., Logunova N.A. Triple fixed-dose combination in the treatment of hypertension: the results of the Russian observational study TRICOLOR. Russian Journal of Cardiology. 2020; 25(10): 4130. https://doi.org/10.15829/1560-4071-2020-4130 (In Russ.).]
  75. Logunova N., Karpov Yu., Khomitskaya Yu., Kvasnikov B. Baseline characteristics, antihypertensive effectiveness, and treatment adherence in hypertensive patients depending on age: post-hoc analysis of the tricolor study. J Hypert. 2022; 40(Suppl 1): e98. https://doi.org/10.1097/01.hjh.0000836200.79405.6c
  76. Girerd X., Hanon O., Anagnostopoulos K., et al. Evaluation de l’observance du traitement antihypertenseur par un questionnaire: mise au point et utilisation dans un service spécialisé [Assessment of antihypertensive compliance using a self-administered questionnaire: development and use in a hypertension clinic]. Presse Med. 2001; 30(21): 1044–1048 (In French).
  77. Бойцов С.А., Карпов Ю.А., Бурцев Ю.П., Хомицкая Ю.В. От имени всех участников исследования СТИЛЬ. Эффективность фиксированной комбинации бисопролола и периндоприла в зависимости от используемых доз у пациентов с артериальной гипертонией и СТабИЛЬной ишемической болезнью сердца в реальной клинической практике (исследование СТИЛЬ). Атмосфера. Новости Кардиологии. 2021; 1: 30–38. https://doi.org/10.24412/2076-4189-2021-12344 [Boitsov S.A., Karpov Yu.A., Burtsev Yu.P., Khomitskaya Yu.V. On behalf of all participants of the STYLE study. The efficacy of fixed combination of bisoprolol and perindopril depending on the doses used in patients with arterial hypertension and stable coronary heart disease in real clinical practice (STYLE Study). Atmosphere. Cardiology News. 2021; 1: 30–38. https://doi.org/10.24412/2076-4189-2021-12344 (In Russ.).]
  78. Гусейнова Э.Т., Лукина Ю.В., Кутишенко Н.П. и др. Проблема и факторы приверженности лечению больных хронической сердечной недостаточностью по данным амбулаторного регистра. Профилактическая медицина. 2023; 26(11): 39–44. https://doi.org/10.17116/profmed20232611139 [Guseynova E.T., Lukina Yu.V., Kutishenko N.P., et al. Problem and factors of patients with chronic heart failure treatment compliance according to outpatient registry. Russian Journal of Preventive Medicine. 2023; 26(11): 39–44. https://doi.org/10.17116/profmed20232611139 (In Russ.).]
  79. Кужелева Е.А., Федюнина В.А., Гарганеева А.А. Приверженность лечению и качество жизни больных сердечно-сосудистыми заболеваниями на амбулаторном этапе оказания медицинской помощи. Евразийский кардиологический журнал. 2020; (2): 34–40. https://doi.org/10.38109/2225-1685-2020-2-34-40 [Kuzheleva E.A., Fedyunina V.A., Garganeeva A.A. Adherence to treatment and quality of life of patients with cardiovascular diseases at the outpatient treatment stage of medical care. Eurasian Heart Journal. 2020; (2): 34–40. https://doi.org/10.38109/2225-1685-2020-2-34-40 (In Russ.).]
  80. Mitsios J.P., Ekinci E.I., Mitsios G.P., et al. Relationship Between Glycated Hemoglobin and Stroke Risk: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2018; 7(11): e007858. https://doi.org/10.1161/jaha.117.007858
  81. World Health Organization. Diabetes. 2022. Nov. 14, 2024. Available at: https://www.who.int/news-room/fact-sheets/detail/diabetes (Accessed: 01.08.2025).
  82. Morrish N.J., Wang S.L., Stevens L.K., et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001; 44. Suppl 2: S14–S 21. https://doi.org/10.1007/pl00002934
  83. White J.R. Jr. Advances in Insulin Therapy: A Review of New Insulin Glargine 300 Units/mL in the Management of Diabetes. Clin Diabetes. 2016; 34(2): 86–91. https://doi.org/10.2337/diaclin.34.2.86
  84. Polonsky W.H., Fisher L., Guzman S., et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005; 28(10): 2543–2545. https://doi.org/10.2337/diacare.28.10.2543
  85. Rathmann W., Czech M., Franek E., Kostev K. Treatment persistence in the use of basal insulins in Poland and Germany. Int J Clin Pharmacol Ther. 2017; 55(2): 119–125. https://doi.org/10.5414/cp202772
  86. Hamersky C.M., Fridman M., Gamble C.L., Iyer N.N. Injectable Antihyperglycemics: A Systematic Review and Critical Analysis of the Literature on Adherence, Persistence, and Health Outcomes. Diabetes Ther. 2019; 10(3): 865–890. https://doi.org/10.1007/s13300-019-0617-3
  87. McGovern A., Tippu Z., Hinton W., et al. Comparison of medication adherence and persistence in type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab. 2018; 20(4): 1040–1043. https://doi.org/10.1111/dom.13160
  88. Gimeno E.J., Bøgelund M., Larsen S., et al. Adherence and Persistence to Basal Insulin Among People with Type 2 Diabetes in Europe: A Systematic Literature Review and Meta-analysis. Diabetes Ther. 2024; 15: 1047–1067. https://doi.org/10.1007/s13300-024-01559-w
  89. Cheiloudaki E., Alexopoulos E.C. Adherence to treatment in stroke patients. Int J Environ Res Public Health. 2019; 16(2): 196. https://doi.org/10.3390/ijerph16020196
  90. Захарова Е.В. Теоретические концепции и методы исследования комплаенса и приверженности лечению. Теоретическая и экспериментальная психология. 2019; 12(3): 96–110 [Zakharova E.V. Theoretical concepts and research methods for compliance and treatment adherence. Theoretical and Experimental Psychology. 2019; 12(3): 96–110 (In Russ.).]



Creative Commons License
The content is available under the Creative Commons Attribution 4.0 License.

©


This is an open article under the CC BY 4.0 license. Published by the National Medical Research Center for Rehabilitation and Balneology.